Products

Dabigatran Etexilate (DE) is a potent, synthetic, non-peptide competitive, rapidly acting oral direct thrombin inhibitor (oral DTI). It is an anticoagulant medication which can be taken by mouth. It is used as an alternative to warfarin.

Dabigatran Etexilate (DE) is the oral pro-drug of the active moiety dabigatran (DAB) and does not possess anticoagulant activity. The pro-drug dabigatran etexilate is used in its salt form dabigatran etexilate mesilate (DEM). That specifically and reversibly inhibits thrombin, the final enzyme in the coagulation cascade. The granted indication is primary prevention of venous thromboembolism (VTE) in patients undergoing elective major orthopedic surgery (MOS). It is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Dexlansoprazole DDR Pellets 17%, 20%, 22.5%, 23% – Suitable for Capsules (Dose: 30 mg, 60 mg)

The pharmaceutical form of dexlansoprazole is based on the unique technology of modified dual release. The active ingredient is released in two phases at different pH values and with a time interval. Consequently, the drug achieves two peak concentrations in the blood, and the total serum concentration of dexlansoprazole is three times higher.

• MKPPL has developed Dexlansoprazole pellets by aqueous technology to match the dissolution profile of Dexlansoprazole Pellets with Innovator.
• The product developed is comparable with innovator with respect to dissolution profile of the marketed product.
• We offer development services if different formulations/dosages/strengths are required
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Duloxetine HCL DR Pellets – Suitable for filling 20mg, 40mg & 60mg Capsules.

• Release pattern compared with innovator
• MKPPL objective is to develop duloxetine pellets by aqueous technology. Pellets developed by aqueous technology have advantage of avoiding the use of organic solvents.
• All the ingredients are available for both FBC process and all the equipment’s including analytical instruments like HPLC, FTIR, GC and dissolution apparatus are available to develop duloxetine pellets.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Erlotinib MUPs / Granules

• The Development of premix of Erlotinib was done by Murli Krishna Pharma with the aim of overcoming:Poor bio-availability owing to poor solubility and reduction in toxicity through matrix based encapsulation.
• The granules are ready for compression. The strength of the granules is 50% w/w. The granules can be employed for compression of tablets having the following strength: 50 mg/tablet (Tablet weight 100 mg) 100 mg/tablet (tablet weight 200 mg) and 150 mg/tablet (tablet weight 300 mg).
• We offer development services in case of a requirement for different formulations/dosages/strengths
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Esomeprazole EC Pellets / MUPS / Granules 8.5%, 22.5% – Suitable for Capsules, Tablets (dose: 20 mg, 40 mg)

• Esomeprazole is the chiral form of omeprazole. The product is manufactured as enteric coated pellets by aqueous technology to match with Innovator without use of organic solvent.
• The product developed is comparable with innovator with respect to dissolution profile of the marketed product.
• The quality of the pellets is based on the in-vitro dissolution test besides the assay and the impurity profile. The time dissolution values are direct measures of the coating efficiency and hence optimum therapeutic efficacy as it has a co-relation with in-vivo behaviors.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Esomeprazole is also proton pump inhibitor and is one of the blockbuster molecule that is used in the treatment of ulcer.

Everolimus Granules – Available as Nanoparticles with 2.68% & 5% Strengths.

• MKPPL is the first to come up with pellet based approach for immune suppressants.
• Facilitates direct filling into capsules and can be easily employed in tableting. Nano particles can be effectively used for manufacturing of ointments (Tacrolimus) and solutions (Everolimus).
• MKPPL pellet advantages includes using a micro emulsion technology. No cyclization of the drug, hence less delta lactones formation.
• Coated pellets, hence the formulator does not require a contained facility for finished formulation.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Itraconazole Pellets 22%, 40% – Suitable for Capsules (Dose: 100 mg, 200 mg)

Itraconazole belongs to the family of medications called antifungals. It is used to treat certain types of fungal infections, both internally (inside the body) and externally (skin and nails).

• Itraconazole is used for the treatment of fungal infections in both HIV- and non-HIV-infected individuals.
• The objective of developing Itraconazole pellets by aqueous technology is to match the dissolution profile of Itraconazole Pellets with SPORANOX without use of organic solvent.
• The product developed is comparable with innovator with respect to dissolution profile of the marketed product.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Lansoprazole EC Pellets Suitable for filling in 15mg & 30mg Capsules, MUPS, Premix (sachet) & 30mg Tablets.

Lansoprazole is a second-generation proton pump inhibitor and is one of the blockbuster molecule that is used in the treatment of ulcers.

• Release pattern compared with innovator -Prevacid delayed-release capsules and Prevacid solutab delayed-release orally disintegrating tablets.
• A comparative dissolution was conducted for Lansoprazole capsules of Murli Krishna Pharma and prevacid capsules which compare favorably.
• The focal intent of the MKPPL was to develop a stable; pharmaceutically equivalent, robust and delayed release micro pellet formulation of Lansoprazole for both capsule and orally disintegrating tablets.
• Offer complete technical package for registrations in all regulated/semi regulated markets.